Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19 by V. T. Ivashkin, R. V. Maslennikov, E. V. Vasilieva, M. L. Chipurik, P. A. Semikova, V. V. Semenets, T. A. Russkova

Subjects: Get full text

IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with lim... by John S. Schardt, Even Walseng, Kim Le, Chunning Yang, Pooja Shah, Ying Fu, Kausar Alam, Cathryn R. Kelton, Yu Gu, Fengying Huang, Jia Lin, Wenhai Liu, Andrew Dippel, Hanzhi Zhang, Kathy Mulgrew, Stacy Pryts, Vijaykumar Chennupati, Hung-Chang Chen, Jessica Denham, Xiaoru Chen, Pallab Pradhan, Yuling Wu, Colin Hardman, Chihao Zhao, Michael Kierny, Yang Song, Simon J. Dovedi, Saso Cemerski, Yariv Mazor

Subjects: Get full text

Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy by Amelia C. McCue, Stephen J. Demarest, Karen J. Froning, Michael J. Hickey, Stephen Antonysamy, Brian Kuhlman

Subjects: Get full text

Late-onset and relapsed cytokine release syndrome after nivolumab treatment in a patient with head and neck squamous cell carcinoma: a case report by Tomoyuki Otsuka, Yoshiki Kojitani, Fumio Imamura, Junko Fukutake, Minako Nishio, Takashi Fujii, Toshihiro Kudo

Subjects: Get full text

Management of chimeric antigen receptor T-cell-related toxicity of a patient affected by cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, follo... by G. Menardi, A. Castellino, C. Castellino, M. E. Bersia, E. Grande, G. Fraternali, M. Massaia, C. Fruttero

Subjects: Get full text